Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors

Pasireotide long-acting repeatable (LAR) is a novel somatostatin analog (SSA) with avid binding affinity to somatostatin receptor subtypes 1, 2, 3 (SSTR(1,2,3)) and 5 (SSTR(5)). Results from preclinical studies indicate that pasireotide can inhibit neuroendocrine tumor (NET) growth more robustly tha...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Endocr Relat Cancer
Autors principals: Cives, M, Kunz, P L, Morse, B, Coppola, D, Schell, M J, Campos, T, Nguyen, P T, Nandoskar, P, Khandelwal, V, Strosberg, J R
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4643672/
https://ncbi.nlm.nih.gov/pubmed/25376618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-14-0360
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars